The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality

Biochemical and Biophysical Research Communications

Volumn 439, Issue 4, 2013, Pages 419-426

  Hitomi, Toshiaki ^a   Habu, Toshiyuki ^a   Kobayashi, Hatasu ^a   Okuda, Hiroko ^a   Harada, Kouji H ^a   Osafune, Kenji ^b   Taura, Daisuke ^a   Sone, Masakatsu ^a   Asaka, Isao ^b   Ameku, Tomonaga ^b   Watanabe, Akira ^b   Kasahara, Tomoko ^b   Sudo, Tomomi ^b   Shiota, Fumihiko ^b   Hashikata, Hirokuni ^a   Takagi, Yasushi ^a   Morito, Daisuke ^c   Miyamoto, Susumu ^a   Nakao, Kazuwa ^a   Koizumi, Akio ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO SANGYO UNIVERSITY   (Japan)

Author keywords

Genomic instability; IPS cells; MAD2; Mitotic phase; Moyamoya disease; Rs112735431

Indexed keywords

PROTEIN MAD2;

ANEUPLOIDY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; HELA CELL; HUMAN; M PHASE CELL CYCLE CHECKPOINT; METAPHASE; MITOSIS; MITOSIS INHIBITION; MOYAMOYA DISEASE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMETAPHASE; PROTEIN FOLDING; PROTEIN LOCALIZATION;

GENOMIC INSTABILITY; IPS CELLS; MAD2; MITOTIC PHASE; MOYAMOYA DISEASE; RS112735431;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOMIC INSTABILITY; GENOTYPE; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAD2 PROTEINS; MITOSIS; MOYAMOYA DISEASE; PHENOTYPE; PLURIPOTENT STEM CELLS; UBIQUITIN-PROTEIN LIGASES;

EID: 84884702763     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.067     Document Type: Article

References (23)

1. Suzuki J., Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch. Neurol. 1969, 20:288-299.
2. Takeuchi K., Shimizu K. Hypogenesis of bilateral internal carotid arteries. Brain Nerv. 1957, 9:37-43.
3. Kuroda S., Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008, 7:1056-1066.
4. Miao W., Zhao P.L., Zhang Y.S., Liu H.Y., Chang Y., Ma J., Huang Q.J., Lou Z.X. Epidemiological and clinical features of Moyamoya disease in Nanjing. China, Clin. Neurol. Neurosurg. 2010, 112:199-203.
5. Scott R.M., Smith E.R. Moyamoya disease and moyamoya syndrome. N. Engl. J. Med. 2009, 360:1226-1237.
6. Veeravagu A., Guzman R., Patil C.G., Hou L.C., Lee M., Steinberg G.K. Moyamoya disease in pediatric patients: outcomes of neurosurgical interventions. Neurosurg. Focus 2008, 24:E16.
7. Liu W., Morito D., Takashima S., Mineharu Y., Kobayashi H., Hitomi T., Hashikata H., Matsuura N., Yamazaki S., Toyoda A., Kikuta K., Takagi Y., Harada K.H., Fujiyama A., Herzig R., Krischek B., Zou L., Kim J.E., Kitakaze M., Miyamoto S., Nagata K., Hashimoto N., Koizumi A. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE 2011, 6:e22542.
8. T. Hitomi, Habu, T., Kobayashi, H., Okuda, H., Harada, HK, Osafune, K., Taura, D., Sone, M., Adaka, I., Ameku, T., Watanabe, A., Kasahara, T., Sudo, T., Shiota, F., Hashikata, H., Takagi, Y., Morito, D., Miyamoto, S., Nakao K., and Koizumi, A., Down-regulation of Securin by the variant RNF213 R4810K may likely reduce angiogenic activity of induced pluripotent stem cells- derived vascular endothelial cells from moyamoya patients, Biochem. Biophys. Res. Commun. 438, (2013), 13-19.
9. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
10. Howell B.J., Hoffman D.B., Fang G., Murray A.W., Salmon E.D. Visualization of Mad2 dynamics at kinetochores, along spindle fibers, and at spindle poles in living cells. J. Cell Biol. 2000, 150:1233-1250.
11. Li Y., Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 1996, 274:246-248.
12. Tidyman W.E., Rauen K.A. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Exp. Rev. Mol. Med. 2008, 10:e37.
13. Kamath B.M., Spinner N.B., Emerick K.M., Chudley A.E., Booth C., Piccoli D.A., Krantz I.D. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004, 109:1354-1358.
14. Noseda M., Chang L., McLean G., Grim J.E., Clurman B.E., Smith L.L., Karsan A. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol. Cell. Biol. 2004, 24:8813-8822.
15. Koizumi A., Kobayashi H., Hitomi T. Genes associated with moyamoya syndrome and disease. No Shinkei Geka 2012, 40:105-118.
16. Milliat F., Francois A., Isoir M., Deutsch E., Tamarat R., Tarlet G., Atfi A., Validire P., Bourhis J., Sabourin J.C., Benderitter M. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. Am. J. Pathol. 2006, 169:1484-1495.
17. Daum J.R., Wren J.D., Daniel J.J., Sivakumar S., McAvoy J.N., Potapova T.A., Gorbsky G.J. Ska3 is required for spindle checkpoint silencing and the maintenance of chromosome cohesion in mitosis. Curr. Biol. 2009, 19:1467-1472.
18. Hornig N.C., Knowles P.P., McDonald N.Q., Uhlmann F. The dual mechanism of separase regulation by securin. Curr. Biol. 2002, 12:973-982.
19. Holt L.J., Krutchinsky A.N., Morgan D.O. Positive feedback sharpens the anaphase switch. Nature 2008, 454:353-357.
20. Michel L., Diaz-Rodriguez E., Narayan G., Hernando E., Murty V.V., Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc. Natl. Acad. Sci. USA 2004, 101:4459-4464.
21. Iovino F., Lentini L., Amato A., Di Leonardo A. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol. Cancer 2006, 5:38.
22. Mei J., Huang X., Zhang P. Securin is not required for cellular viability, but is required for normal growth of mouse embryonic fibroblasts. Curr. Biol. 2001, 11:1197-1201.
23. Pfleghaar K., Heubes S., Cox J., Stemmann O., Speicher M.R. Securin is not required for chromosomal stability in human cells. PLoS Biol. 2005, 3:e416.